Spago Nanomedical Investor Relations Material
Latest events
Q1 2025
7 May, 2025
Q4 2024
6 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Spago Nanomedical
Access all reports
Spago Nanomedical AB is a Swedish biotechnology company that specializes in nanomedicine for cancer diagnostics and treatment. The company is advancing two main projects: SpagoPix and Tumorad. SpagoPix is an MRI contrast agent under clinical development, aimed at improving cancer diagnostics by selectively enhancing tumor visibility in breast, liver, and pancreatic cancers. Tumorad is a radionuclide therapy that targets cancer cells using nanoparticles, currently in preclinical stages for treating advanced cancers. Spago Nanomedical is based in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
SPAGO
Country
🇸🇪 Sweden